Business Wire

Boomi Recognized as a Leader for the 11th Time in the 2025 Gartner® Magic Quadrant™ for Integration Platform as a Service

21.5.2025 17:30:00 CEST | Business Wire | Press release

Share

Boomi Believes Its Leadership in AI, API Management, and Data Management Advancements Will Drive Strong Customer and Partner Momentum

Boomi™, the leader in AI-driven automation, today announced it has been recognized as a Leader in the 2025 Gartner® Magic Quadrant™ for Integration Platform as a Service (iPaaS), for the 11th consecutive time – the longest in the report’s history.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521105444/en/

In our opinion, Boomi’s continued industry recognition reflects its unwavering commitment to innovation, customer success, and ecosystem growth. Over the past year, Boomi has accelerated its investments in AI agent management, API management, and data management to help enterprises connect everything with one platform and drive intelligent automation at scale.

Key advancements include:

  • Launch of Boomi Agentstudio for AI Agent Management: Boomi recently introduced the only full agent lifecycle management solution that allows organizations to simply design, govern, and orchestrate all AI agents at scale, helping unlock hyperproductivity responsibly.
  • Comprehensive API Management Capabilities: Boomi’s expanded API Management capabilities provide cloud-scale APIM and address the growing problem of API sprawl through federated governance of all APIs — adding security, visibility, and value across the enterprise.
  • Modern Data Integration: With the addition ofBoomi Data Integration (formerly Rivery), customers can leverage a single platform for integrating apps, data, APIs, and AI agents. Boomi Data Integration complements existing Boomi DataHub capabilities that provide synchronization and governance as the foundation for trusted data.

Customer and Partner Momentum Accelerates

With more than 23,000 customers globally, Boomi continues to be the trusted integration and automation partner for enterprises across industries, including customers like Lego, Tropicana, and Moderna, who rely on Boomi to connect and automate their business-critical applications and data.

Boomi’s thriving partner network has also seen significant expansion, with leading global system integrators (GSIs), independent software vendors (ISVs), and cloud hyperscalers deepening their collaboration with Boomi to deliver cutting-edge integration and automation solutions. Boomi’s recent strategic agreements with AWS and ServiceNow enhance customer experiences through AI-powered self-service solutions.

A Proven Leader in Integration and Automation

“As organizations continue their journey to becoming AI-driven enterprises, integration and automation have never been more critical,” said Steve Lucas, Chairman and CEO at Boomi. “I believe Boomi’s continued recognition as a Leader in the Gartner Magic Quadrant for iPaaS underscores our relentless focus on innovation and our commitment to enabling our customers and partners to achieve their digital transformation goals. We are honored to be a Leader in this category and remain dedicated to delivering the most advanced, AI-enabled automation platform on the market.”

View the 2025 Gartner Magic Quadrant for iPaaS here.

Additional Resources

Gartner Disclaimer:

Gartner® Magic Quadrant™ for Integration Platform as a Service, Andrew Humphreys, Andrew Comes, Keith Guttridge, Allan Wilkins, May 19, 2025.

Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Note: Boomi was recognized as Dell Boomi from 2014 to 2019.

About Boomi

Boomi, the leader in AI-driven automation, helps organizations around the world automate and streamline critical processes to achieve business outcomes faster. Harnessing advanced AI capabilities, the Boomi Enterprise Platform seamlessly connects systems and manages data flows with API management, integration, data management, and AI orchestration in one comprehensive solution. With over 23,000 customers globally and a network of 800+ partners, Boomi is revolutionizing the way enterprises of all sizes achieve business agility and operational excellence. Discover more at boomi.com.

© 2025 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250521105444/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye